Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.50 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.50 |
| ▸ | SPR | P35270 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 8/20 | 0.42 |
| ▸ | EP300 | Q09472 | 7/20 | 0.42 |
| ▸ | BRD4 | O60885 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 2/20 | 0.38 |
| ▸ | RBP4 | P02753 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5645375 | 0.89 | DPP4 (0.52) | DPP4DPP8DPP7DPP9SPR | |
| SCHEMBL5644483 | 0.88 | DPP4 (0.50) | DPP4DPP8DPP7DPP9RBP4 | |
| SCHEMBL14970423 | 0.87 | MAPK1 (0.56) | DPP4DPP8DPP7DPP9SPR | |
| SCHEMBL23881432 | 0.86 | DPP4 (0.40) | DPP4DPP8DPP7DPP9SPR | |
| SCHEMBL17868650 | 0.84 | CREBBP (0.43) | DPP4DPP8DPP7DPP9CREBBP | |
| SCHEMBL16219036 | 0.83 | DPP4 (0.52) | DPP4DPP8DPP7DPP9SPR | |
| SCHEMBL1009435 | 0.81 | DPP4 (0.46) | DPP4DPP8DPP7DPP9SPR | |
| SCHEMBL20818349 | 0.80 | CREBBP (0.44) | CREBBPEP300BRD4MAPK1 | |
| SCHEMBL17785675 | 0.77 | CREBBP (0.47) | CREBBPEP300BRD4MAPK1 | |
| SCHEMBL5953472 | 0.77 | HCAR2 (0.56) | CREBBPEP300BRD4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023139085-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
| EP-1589969-A4 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7265128-B2 | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20060069116-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-03-30 | — | — | US | disclosed |
| EP-1589969-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co. Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004064778-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO. INC. (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069116-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP7 3/4885 |
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRM1, GRIK1 | DPP4 4270/4885DPP8 3789/4885DPP7 4317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.